Similar articles

• Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

  Ryan GJ, Jobe LJ, Martin R. Ryan GJ, et al. Clin Ther. 2005 Oct;27(10):1500-12. doi: 10.1016/j.clinthera.2005.10.009. Clin Ther. 2005. PMID: 16330288 Review.
• Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

  Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C. Maggs DG, et al. Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60. doi: 10.1002/dmrr.419. Diabetes Metab Res Rev. 2004. PMID: 14737746 Clinical Trial.
• Pramlintide: FDA wants more.

  [No authors listed] [No authors listed] Diabetes Obes Metab. 2001 Oct;3(5):386. Diabetes Obes Metab. 2001. PMID: 11710342 No abstract available.
• Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?

  Edelman SV, Garg S, Kolterman OG. Edelman SV, et al. Nat Clin Pract Endocrinol Metab. 2007 May;3(5):E1; discussion E2. doi: 10.1038/ncpendmet0506. Nat Clin Pract Endocrinol Metab. 2007. PMID: 17452962 No abstract available.
• Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.

  Hoogwerf BJ. Hoogwerf BJ. Cleve Clin J Med. 2006 May;73(5):477-84. doi: 10.3949/ccjm.73.5.477. Cleve Clin J Med. 2006. PMID: 16708716 Review.